Sign In
Buy NVTA
$0.0190
+0 (+0%)
At Close: May 13, 2024
Could Invitae Corporation’s (NYSE:NVTA) Investor Composition Influence The Stock Price?
01:51pm, Monday, 13'th Apr 2020
If you want to know who really controls Invitae Corporation (NYSE:NVTA), then you'll have to look at the makeup of its...
Zacks Investment Research Upgrades InVitae (NYSE:NVTA) to "Buy"
09:22am, Saturday, 11'th Apr 2020
Zacks Investment Research upgraded shares of InVitae (NYSE:NVTA) from a hold rating to a buy rating in a research note published on Tuesday, Zacks.com reports. Zacks Investment Research currently has
Stoke Therapeutics (NASDAQ:STOK) Rating Lowered to Sell at BidaskClub
08:58am, Saturday, 11'th Apr 2020
Stoke Therapeutics (NASDAQ:STOK) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, BidAsk
InVitae (NYSE:NVTA) Trading 2.7% Higher
07:48am, Saturday, 11'th Apr 2020
InVitae Corp (NYSE:NVTA) shares traded up 2.7% during mid-day trading on Thursday . The company traded as high as $13.57 and last traded at $13.90, 1,165,951 shares changed hands during mid-day tradin
Organovo Up On Cancelled Merger, And Other News: The Good, Bad And Ugly Of Biopharma
11:52am, Thursday, 09'th Apr 2020
Organovo is up after calling off a merger with Tarveda. Roche's risdiplam is delayed by FDA action. Invitae is up on launch of new telemedicine enhancement.
Invitae: Very Painful Capital Raise
10:20pm, Tuesday, 07'th Apr 2020
Equity offering priced in single digits. Outstanding share count surges to new high. Management details some interesting items.
Invitae launches enhanced capabilities to support telemedicine
11:30am, Tuesday, 07'th Apr 2020
Invitae (NYSE: NVTA), a leading medical genetics company today announced new tools to help obstetrician/gynecologists, oncologists, genetic counselors and other clinicians who order genetic tests via
Q1 2020 Earnings Forecast for InVitae Corp Issued By Oppenheimer (NYSE:NVTA)
05:18am, Tuesday, 07'th Apr 2020
InVitae Corp (NYSE:NVTA) – Analysts at Oppenheimer reduced their Q1 2020 earnings per share estimates for shares of InVitae in a research report issued to clients and investors on Wednesday, April 1
Invitae Corporation (NYSE: NVTA) today announced the closing of its underwritten public offering of 20,444,444 shares of its common stock, including 2,666,666 shares sold pursuant to the exercise in f
Dublin, April 06, 2020 -- The "U.S. Hematologic Malignancies Testing Market: Focus on Product, Disease, Technology, End User, Country Data and Competitive Landscape -.
Cramer Gives His Opinion Alteryx, Johnson & Johnson And More
11:28am, Monday, 06'th Apr 2020
Jim Cramer said on "Mad Money Lightning Round" he is a buyer of Alteryx Inc (NYSE: AYX) because it has a great growth.
Instead of InVitae Corp (NYSE: NVTA), Cramer would...
InVitae (NYSE:NVTA) Price Target Lowered to at Oppenheimer
10:00am, Monday, 06'th Apr 2020
InVitae (NYSE:NVTA) had its target price cut by Oppenheimer from to in a research report report published on Thursday morning, The Fly reports. Several other research firms have also recently issued r
AQR Capital Management LLC Sells 39,297 Shares of InVitae Corp (NYSE:NVTA)
08:34am, Monday, 06'th Apr 2020
AQR Capital Management LLC decreased its holdings in shares of InVitae Corp (NYSE:NVTA) by 26.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities
Here's Why Invitae Tumbled 32.9% in March
05:15am, Monday, 06'th Apr 2020
Growth stocks were among the most severely punished during the recent stock market crash.
InVitae Corp Expected to Earn Q1 2020 Earnings of ($0.93) Per Share (NYSE:NVTA)
05:12am, Monday, 06'th Apr 2020
InVitae Corp (NYSE:NVTA) – Equities researchers at SVB Leerink lowered their Q1 2020 earnings per share estimates for shares of InVitae in a research report issued on Wednesday, April 1st. SVB Leeri
